CNCE stock forecast
Our latest prediction for Concert Pharmaceuticals, Inc.'s stock price was made on the Aug. 17, 2020 when the stock price was at 10.44$.
In the short term (2weeks), CNCE's stock price should underperform the market by -2.58%. During that period the price should oscillate between -10.11% and +11.10%.
In the medium term (3months), CNCE's stock price should underperform the market by -6.50%. During that period the price should oscillate between -39.17% and +25.42%.Get email alerts
Create a solid portfolio with CNCE
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
At the moment the company generates 6M USD in revenues.
On its last earning announcement, the company reported a loss of -2.69$ per share.
The book value per share is 8.55$
Three months stock forecastAug. 17, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|